Merrill et al. SLEek LTE. ABBV-599 (Elsubrutinib and Upadacitinib Combination) and Upadacitinib monotherapy in SLE. 104 week data. SRI-4 85.4%, 82.1%, and 61.3% in the ABBV-599 HD, UPA 30 mg, and PBO to ABBV-599 HD group @RheumNow #ACR24 Abstr#2577 https://t.co/wc6Mb13U4O https://t.co/Xu1pMhAUrG